Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding HRTS?
Track your performance easily
HRTS Price & Analysis
HRTS ETF Chart & Stats
Day’s Range― - ―
52-Week Range$26.26 - $35.58
Previous Close$32.53
VolumeN/A
Average Volume (3M)27.07K
AUM60.96M
NAV32.45
Expense Ratio0.75%
Holdings Count45
Beta1.20
Inception DateNov 21, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Shares OutstandingN/A
Standard Deviation0.09
10 Day Avg. Volume15,363
30 Day Avg. Volume27,067
Alpha-0.00718
Tema Cardiovascular and Metabolic ETF (HRTS) Fund Flow Chart
Tema Cardiovascular and Metabolic ETF (HRTS) 1 year Net Flows: $58M
HRTS ETF News
HRTS ETF FAQ
What was HRTS’s price range in the past 12 months?
HRTS lowest ETF price was $26.26 and its highest was $35.58 in the past 12 months.
What is the AUM of HRTS?
As of May 07, 2024 The AUM of HRTS is 60.96M.
Is HRTS overvalued?
According to Wall Street analysts HRTS’s price is currently Undervalued.
Does HRTS pay dividends?
HRTS does not currently pay dividends.
How many shares outstanding does HRTS have?
Currently, no data Available
Which hedge fund is a major shareholder of HRTS?
Currently, no hedge funds are holding shares in HRTS
HRTS ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Amgen Inc
5.36%
Vertex Pharmaceuticals Inc.
5.32%
Eli Lilly And Company
4.92%
Novo Nordisk A/S (UK)
4.56%
Dexcom
4.26%
Insulet
2.95%
Cytokinetics
2.87%
Medtronic
2.84%
Edwards Lifesciences Corp.
2.80%
Alnylam Pharmaceuticals
2.75%
Total38.62%
ETF Description
Tema Cardiovascular and Metabolic ETF
HRTS is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.